Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson's disease.

Wei-Yi Cheng, Michael Lindemann, Gennaro Pagano, Wagner Zago, Hanno Svoboda, Anne Boulay, Jens Schjodt-Eriksen, Detlef Wolf, Yan-Ping Zhang, Florian Lipsmeier, Werner L Popp, Atieh Bamdadian, Brit Mollenhauer, Timothy Kilchenmann, Ekaterina Volkova-Volkmar, Ronald B Postuma, Kirsten I Taylor

Journal: Scientific reports 2022;12(1):12081

PMID: 35840753

Abstract

Digital health technologies enable remote and therefore frequent measurement of motor signs, potentially providing reliable and valid estimates of motor sign severity and progression in Parkinson's disease (PD). The Roche PD Mobile Application v2 was developed to measure bradykinesia, bradyphrenia and speech, tremor, gait and balance. It comprises 10 smartphone active tests (with ½ tests administered daily), as well as daily passive monitoring via a smartphone and smartwatch. It was studied in 316 early-stage PD participants who performed daily active tests at home then carried a smartphone and wore a smartwatch throughout the day for passive monitoring (study NCT03100149). Here, we report baseline data. Adherence was excellent (96.29%). All pre-specified sensor features exhibited good-to-excellent test-retest reliability (median intraclass correlation coefficient = 0.9), and correlated with corresponding Movement Disorder Society-Unified Parkinson's Disease Rating Scale items (rho: 0.12-0.71). These findings demonstrate the preliminary reliability and validity of remote at-home quantification of motor sign severity with the Roche PD Mobile Application v2 in individuals with early PD.

© 2022. The Author(s).

Address: Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland. [email protected].; Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland.; Department of Neurology, McGill University, Montreal General Hospital, Montreal, QC, Canada.; Paracelsus-Elena-Klinik, Kassel, Germany.; Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.; Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.; Prothena Biosciences Inc, South San Francisco, CA, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.